MedTrace Logo

Efficacy and Long-Term Safety of Vildagliptin as Add-on Therapy to Metformin in Patients With Type 2 Diabetes

NCT00860288 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 1988

Last updated 2020-12-29

No results posted yet for this study

Summary

This is a 2-3 period parallel group study with an adaptive element in Type 2 diabetes patients receiving vildagliptin as add-on therapy to metformin

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

Vildagliptin

DRUG

Metformin

DRUG

Placebo

DRUG

Sitagliptin

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
78 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-02-28
Primary Completion
2011-03-31
Completion
2011-03-31

Countries

  • Argentina
  • Austria
  • Belgium
  • Finland
  • Germany
  • Greece
  • Guatemala
  • Hungary
  • India
  • Israel
  • Italy
  • Latvia
  • Lithuania
  • Mexico
  • Norway
  • Peru
  • Poland
  • Romania
  • Slovakia
  • South Korea
  • Venezuela

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00860288 on ClinicalTrials.gov